Business Description: Greenwich LifeSciences (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.
Substantial Unmet Need: One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021. In the adjuvant setting, a HER2/neu positive patient typically receives Herceptin in the first year following breast cancer surgery, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years following surgery. Herceptin has been shown to reduce recurrence rates by 50%, from 25% to 12%, in the adjuvant setting. In the neoadjuvant setting, a HER2/neu 3+ patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive Herceptin or Kadcyla, a more potent form of Herceptin, following surgery. Kadcyla has been shown to reduce recurrence rates by 50%, from 22% to 11%, in the neoadjuvant setting. Accordingly, the Company believes that GP2 immunotherapy may be effective in safely addressing the 50% of recurring patients who do not respond to either Herceptin or Kadcyla.
Statistically Significant Phase IIb Clinical Data in HER2/neu 3+ Over- Expressors: In a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson and completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient was treated, followed, and remained disease free over the first 6 months, which is the time required to reach peak immunity and thus maximum efficacy and protection (p = 0.0338). Furthermore, the GP2 immunotherapy elicited a potent immune response measured by local skin tests and immunological assays. Of the 146 patients who have been treated with GP2 immunotherapy to date over 4 clinical trials, no serious adverse events were reported related to GP2 immunotherapy, and GP2 immunotherapy was well tolerated. The Phase IIb clinical trial results can be summarized as:
No cancer recurrences if treated, followed, and remained disease-free over the first 6 months
Peak immunity at 6 months
No serious adverse events attributable to treatment
A well tolerated safety profile
Ongoing Phase III Clinical Trial: For the Flamingo-01 Phase III clinical trial, which is conservatively designed to reproduce the Phase IIb clinical trial results, Greenwich LifeSciences is selecting and activating clinical sites from university-based hospitals and cooperative networks in the U.S. and Europe.
Dec 29, 2022
Dec 1, 2022
Aug 11, 2022
Corporate Presentation - September 2022 (PDF)
Corporate Presentation - November 2021 (Webcast)
Snehal PatelCEO & Board Member
“We believe that the potential market for the proposed initial and follow-on indications is large and may reach 30% of breast cancer patients who undergo surgery, which is 2.4 times the current Herceptin adjuvant setting market. Approximately 17,000 new patients may be eligible for GP2 treatment per year, which could save approximately 1,500 to 2,000 lives per year. Our management team and I are excited to have begun the Phase III clinical trial. We look forward to making GP2 available to as many eligible patients as possible.”
Greenwich LifeSciences, Inc.
3992 Bluebonnet Drive Building 14 Stafford, TX 77477
Investor & Public Relations Team T: 832-819-3232 firstname.lastname@example.org
Pacific Stock Transfer Company
Sign me up for: